Continuous Collection of Adeno-Associated Virus from Producer Cell Medium Significantly Increases Total Viral Yield

被引:35
|
作者
Benskey, Matthew J. [1 ]
Sandoval, Ivette M. [1 ]
Manfredsson, Fredric P. [1 ,2 ]
机构
[1] Michigan State Univ, Coll Human Med, Dept Translat Sci & Mol Med, Grand Rapids, MI USA
[2] Mercy Hlth St Marys, Grand Rapids, MI USA
关键词
GENE DELIVERY; VECTORS; AAV; PURIFICATION; SEROTYPE-1; EXPRESSION; DISEASE; SYSTEM; TYPE-2; MOUSE;
D O I
10.1089/hgtb.2015.117
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The ability to efficiently produce large amounts of high-titer recombinant adeno-associated virus (AAV) is a prerequisite to the continued success of AAV as a gene therapy tool targeted toward large-animal preclinical studies or human clinical therapeutics. Current manufacturing procedures necessitate laborious and time-consuming purification procedures to obtain AAV particles of sufficient titer and purity for these demanding biomedical applications. The finding that AAV can be harvested and purified from producer cell medium may represent an efficient alternative to purifying AAV from cellular lysates. Here we sought to determine the maximum duration of time, and frequency within which AAV can be harvested from producer cell medium, in order to maximize the yield obtained from a single transfection preparation. Human embryonic kidney 293T cells were transfected with polyethylenimine to produce AAV2/5 expressing green fluorescent protein (GFP), and cellular medium was harvested every 2 days until a maximum duration of 19 days posttransfection. AAV2/5-GFP was released into producer cell medium at a steady state until 7 days posttransfection, at which time titers dropped dramatically. Harvesting medium every two days resulted in the maximum yield of AAV from a single preparation, and the cumulative yield of AAV harvested from the producer cell medium was 4-fold higher than the yield obtained from a traditional purification of AAV from cellular lysates. The AAV2/5 harvested from medium within the 7-day collection time-course mediated high levels of transduction in vivo, comparable to AAV2/5 harvested from cellular lysates. AAV purified from cell lysates showed increasing amounts of empty particles at 5 and 7 days posttransfection, whereas AAV purified from cell medium did not show an increase in the amount of empty particles throughout the 7-day time course. Finally, we extended these findings to AAV2/9, demonstrating that a comparable ratio of AAV2/9 particles are also released for up to 7 days posttransfection.
引用
收藏
页码:32 / 45
页数:14
相关论文
共 15 条
  • [1] Manufacturing Recombinant Adeno-Associated Viral Vectors from Producer Cell Clones
    Thorne, Barbara A.
    Takeya, Ryan K.
    Peluso, Richard W.
    HUMAN GENE THERAPY, 2009, 20 (07) : 707 - 714
  • [2] A synthetic platform for developing recombinant adeno-associated virus type 8 producer cell lines
    Lin, Yu-Chieh
    Kuo, Han-Jung
    Lu, Min
    Mahl, Thomas
    Aslanidi, George
    Hu, Wei-Shou
    BIOTECHNOLOGY PROGRESS, 2025,
  • [3] Expression of Viral DNA Polymerase in Synthetic Recombinant Adeno-Associated Virus Producer Cell Line Enhances Full Particle Productivity
    Lin, Yu-Chieh
    Kuo, Han-Jung
    Lu, Min
    Rungkittikhun, Carissa
    Hu, Wei-Shou
    BIOTECHNOLOGY AND BIOENGINEERING, 2024, : 424 - 434
  • [4] A Versatile Adeno-Associated Virus Vector Producer Cell Line Method for Scalable Vector Production of Different Serotypes
    Yuan, Zhenhua
    Qiao, Chunping
    Hu, Peiqi
    Li, Juan
    Xiao, Xiao
    HUMAN GENE THERAPY, 2011, 22 (05) : 613 - 624
  • [5] Different protein composition and functional properties of adeno-associated virus-6 vector manufactured from the culture medium and cell lysates
    Denard, Jerome
    Jenny, Christine
    Blouin, Veronique
    Moullier, Philippe
    Svinartchouk, Fedor
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2014, 1 : 14031
  • [6] Mammalian Stable Cell Platforms for Recombinant Adeno-associated Virus (rAAV) Production: Development Strategies and their Impact on Viral Productivity
    Fernandes, Sofia
    Diogo, Joana
    Coroadinha, Ana Sofia
    CURRENT GENE THERAPY, 2023, 23 (03) : 184 - 197
  • [7] Adeno-associated virus perfusion enhanced expression: A commercially scalable, high titer, high quality producer cell line process
    Xue, Wei
    Fulco, Cameron
    Sha, Sha
    Alden, Nick
    Panteli, Jan
    Hossler, Patrick
    Warren, James
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (02)
  • [8] A directed evolution approach to select for novel Adeno-associated virus capsids on an HIV-1 producer T cell line
    Wooley, Dawn P.
    Sharma, Priyanka
    Weinstein, John R.
    Narayan, Poornima Kotha Lakshmi
    Schaffer, David V.
    Excoffon, Katherine J. D. A.
    JOURNAL OF VIROLOGICAL METHODS, 2017, 250 : 47 - 54
  • [9] Rescue of avian adeno-associated virus from a recombinant plasmid containing deletions in the viral inverted terminal repeats
    Wang, Jianye
    Zhu, Liqian
    Zhu, Jun
    Zhang, Xinjun
    Tao, Jie
    Duan, Qiangde
    Zhu, Guoqiang
    ARCHIVES OF VIROLOGY, 2012, 157 (01) : 129 - 134
  • [10] Sequence analysis, viral rescue from infectious clones and generation of recombinant virions of the avian adeno-associated virus
    Estevez, C
    Villegas, P
    VIRUS RESEARCH, 2004, 105 (02) : 195 - 208